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HIV is extremely variable and newly arisen variants may
be rapidly selected upon drug pressure. New antivirals
are available, new therapeutic options are at hand for all
patients, either naïve or multiexperienced. Individuali-
zation is the hallmark of new approaches to antiretroviral
therapies. Knowledge of drug resistance is important to
guide clinicians in devising treatment regimens and to
optimally preserve later treatment options for patients.
This presentation will focus on the new technologies,
methodologies, models and research tools to enhance
detection and interpretation of HIV-1 drug-resistance.
Particular attention will be dedicated to the resistance to
the new antivirals.
The development of the new second-generation
NNRTI etravirine, which has a higher genetic barrier
than the first-generation drugs, has led to new under-
standing of the complexity of NNRTI resistance. To
date, 17 mutations have been identified as being asso-
ciated with etravirine resistance and reduced virological
response.
Integrase inhibitors are very potent drugs providing a
great opportunity for clinicians, to construct new regi-
mens for individuals with HIV infection resistant to all
three traditional classes of antivirals. However, these
drugs have a relatively low genetic barrier to resistance
and thus require both the selection of an optimised
backbone to ensure durable viral suppression and a
clear understanding of their residual activity in a failing
integrase regimen. Resistance tests able to sequence and
detect mutations in integrase are crucial for their proper
use in clinical practice.
Viral escape of entry inhibitors may occur through
‘classic’ viral resistance to the compounds, but also by
usage of alternative cell co-receptors. To date the main
focus of research on co-receptor antagonists has been
on determining and quantifying the CCR5, CXCR4,
dual/mixed coreceptor tropism. Recent data begun to
emerge on how resistance develops with the accumula-
tion of mutations in gp120 to maraviroc, the first-in-
class R5 co-receptor antagonist.
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